Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Phase 1 Active not recruiting 8 enrolled Catherine Bollard

NaSingle-groupOpen-labelTreatment

Summary

This is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT).

Timeline

Start: 2020-05-01
Primary completion: 2025-09
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DD HST-NEETS	Cell therapy	2e+07 unknown	—

Indications

No indication recorded.